Binding of labeled estrogen-albumin conjugates in breast cancer

J. van Marie, J. P. A. Baak, C. J. L. M. Meijer, J. Lindeman

Research output: Chapter in Book/Report/Conference proceedingChapterAcademicpeer-review

Abstract

It was Lee1 who was the first to use an estrogen-bovine serum albumin fluorescein isothiocyanate (O-BSA-FITC) complex in order to demonstrate estrogen binding sites in thin sections of mammary tumors. Synthesis of this O-BSA-FITC complex is relatively simple. This new method had the advantage over autoradiographic methods,2 viz., with respect to technical simplicity and speed. In contrast to immunological methods,1 the advantage of Lee’s method is that no complicated purifications of antigen and antibodies are necessary and, besides, no animals have to be sensitized against either the estrogen receptor proper or estradiol. In his first publication Lee interpreted the fluorescence observed without any restrictions as proof of the presence of biochemically defined estrogen receptors. He did not specify the term receptor, but he implied its identity with the biochemically defined type I estrogen receptor.
Original languageEnglish
Title of host publicationLocalization of Putative Steroid Receptors: Volume II: Clinically Oriented Studies
PublisherCRC Press
Pages113-148
ISBN (Electronic)9781351082600
ISBN (Print)0849360498
DOIs
Publication statusPublished - 2018

Publication series

NameLocalization of Putative Steroid Receptors: Volume II: Clinically Oriented Studies

Cite this

van Marie, J., Baak, J. P. A., Meijer, C. J. L. M., & Lindeman, J. (2018). Binding of labeled estrogen-albumin conjugates in breast cancer. In Localization of Putative Steroid Receptors: Volume II: Clinically Oriented Studies (pp. 113-148). (Localization of Putative Steroid Receptors: Volume II: Clinically Oriented Studies). CRC Press. https://doi.org/10.1201/9781351074155